Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Risankizumab SC Dosing in Healthy Volunteers
NCT05283694Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA) and Crohn's disease (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 140 Days, Time to Maximum Observed Plasma Concentration up to 140 Days and 6 more. Started Sep 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's disease
Beyond the preview
Go deeper on NCT05283694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283694.